Literature DB >> 32078486

Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.

Brett Cucchiara1, Jordan Elm2, J Donald Easton3, Shelagh B Coutts4, Joshua Z Willey5, Michelle H Biros6, Michael A Ross7, S Claiborne Johnston8.   

Abstract

Background and Purpose- While combination aspirin and clopidogrel reduces recurrent stroke compared with aspirin alone in patients with transient ischemic attack (TIA) or minor stroke, the effect on disability is uncertain. Methods- The POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) randomized patients with TIA or minor stroke (National Institutes of Health Stroke Scale score ≤3) within 12 hours of onset to dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel versus aspirin alone. The primary outcome measure was a composite of stroke, myocardial infarction, or vascular death. We performed a post hoc exploratory analysis to examine the effect of treatment on overall disability (defined as modified Rankin Scale score >1) at 90 days, as well as disability ascribed by the local investigator to index or recurrent stroke. We also evaluated predictors of disability. Results- At 90 days, 188 of 1964 (9.6%) of patients enrolled with TIA and 471 of 2586 (18.2%) of those enrolled with stroke were disabled. Overall disability was similar between patients assigned DAPT versus aspirin alone (14.7% versus 14.3%; odds ratio, 0.97 [95% CI, 0.82-1.14]; P=0.69). However, there were numerically fewer patients with disability in conjunction with a primary outcome event in the DAPT arm (3.0% versus 4.0%; odds ratio, 0.73 [95% CI, 0.53-1.01]; P=0.06) and significantly fewer patients in the DAPT arm with disability attributed by the investigators to either the index event or recurrent stroke (5.9% versus 7.4%; odds ratio, 0.78 [95% CI, 0.62-0.99]; P=0.04). Notably, disability attributed to the index event accounted for the majority of this difference (4.5% versus 6.0%; odds ratio, 0.74 [95% CI, 0.57-0.96]; P=0.02). In multivariate analysis, age, subsequent ischemic stroke, serious adverse events, and major bleeding were significantly associated with disability in TIA; for those with stroke, female sex, hypertension, or diabetes mellitus, National Institutes of Health Stroke Scale score, recurrent ischemic stroke, subsequent myocardial infarction, and serious adverse events were associated with disability. Conclusions- In addition to reducing recurrent stroke in patients with acute minor stroke and TIA, DAPT might reduce stroke-related disability. Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT00991029.

Entities:  

Keywords:  aspirin; diabetes mellitus; humans; ischemic attack, transient; stroke

Mesh:

Substances:

Year:  2020        PMID: 32078486      PMCID: PMC7313376          DOI: 10.1161/STROKEAHA.119.027465

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Gender differences in stroke incidence and poststroke disability in the Framingham heart study.

Authors:  Rodica E Petrea; Alexa S Beiser; Sudha Seshadri; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf
Journal:  Stroke       Date:  2009-02-10       Impact factor: 7.914

2.  Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

Authors:  S Claiborne Johnston; Pierre Amarenco; Gregory W Albers; Hans Denison; J Donald Easton; Scott R Evans; Peter Held; Jenny Jonasson; Kazuo Minematsu; Carlos A Molina; Yongjun Wang; K S Lawrence Wong
Journal:  N Engl J Med       Date:  2016-05-10       Impact factor: 91.245

3.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Authors:  Yongjun Wang; Yilong Wang; Xingquan Zhao; Liping Liu; David Wang; Chunxue Wang; Chen Wang; Hao Li; Xia Meng; Liying Cui; Jianping Jia; Qiang Dong; Anding Xu; Jinsheng Zeng; Yansheng Li; Zhimin Wang; Haiqin Xia; S Claiborne Johnston
Journal:  N Engl J Med       Date:  2013-06-26       Impact factor: 91.245

4.  Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial.

Authors:  Brett Cucchiara; Donna Kurowski George; Scott E Kasner; Mikael Knutsson; Hans Denison; Per Ladenvall; Pierre Amarenco; S Claiborne Johnston
Journal:  Neurology       Date:  2019-07-11       Impact factor: 9.910

5.  The cognitive burden of stroke emerges even with an intact NIH Stroke Scale Score: a cohort study.

Authors:  Tatu Kauranen; Siiri Laari; Katri Turunen; Satu Mustanoja; Peter Baumann; Erja Poutiainen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-09-27       Impact factor: 10.154

6.  Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.

Authors:  S Claiborne Johnston; J Donald Easton; Mary Farrant; William Barsan; Robin A Conwit; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch
Journal:  N Engl J Med       Date:  2018-05-16       Impact factor: 91.245

7.  What causes disability after transient ischemic attack and minor stroke?: Results from the CT and MRI in the Triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study.

Authors:  Shelagh B Coutts; Jayesh Modi; Shiel K Patel; Heidi Aram; Andrew M Demchuk; Mayank Goyal; Michael D Hill
Journal:  Stroke       Date:  2012-09-13       Impact factor: 7.914

8.  Confounding by Pre-Morbid Functional Status in Studies of Apparent Sex Differences in Severity and Outcome of Stroke.

Authors:  Christel Renoux; Janie Coulombe; Linxin Li; Aravind Ganesh; Louise Silver; Peter M Rothwell
Journal:  Stroke       Date:  2017-08-10       Impact factor: 7.914

9.  Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.

Authors:  Peter M Rothwell; Ale Algra; Zhengming Chen; Hans-Christoph Diener; Bo Norrving; Ziyah Mehta
Journal:  Lancet       Date:  2016-05-18       Impact factor: 202.731

  9 in total
  5 in total

1.  Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.

Authors:  Zeling Cai; Ruiwen Wang; Heng Wang; Ze Yu; Fei Gao; Yuansheng Liu; Yingbo Kang; Zhuomin Wu
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

2.  Collateral Status and Clinical Outcomes after Mechanical Thrombectomy in Patients with Anterior Circulation Occlusion.

Authors:  Yuzhu Xu; Songtao Guo; Hao Jiang; Hui Han; Jian Sun; Xi Wu
Journal:  J Healthc Eng       Date:  2022-01-25       Impact factor: 2.682

3.  Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke.

Authors:  Lily W Zhou; Lironn Kraler; Adam de Havenon; Maarten G Lansberg
Journal:  J Am Heart Assoc       Date:  2022-06-03       Impact factor: 6.106

4.  Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial.

Authors:  Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Mikael Knutsson; Per Ladenvall; Carlos A Molina; Yongjun Wang; S Claiborne Johnston
Journal:  JAMA Neurol       Date:  2020-11-07       Impact factor: 18.302

5.  Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial.

Authors:  Yongjun Wang; Yuesong Pan; Hao Li; Pierre Amarenco; Hans Denison; Scott R Evans; Anders Himmelmann; Stefan James; Filip Birve; Per Ladenvall; Carlos A Molina; S Claiborne Johnston
Journal:  JAMA Neurol       Date:  2021-09-01       Impact factor: 18.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.